AWHL Aspira Women's Health Inc.
In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 926617 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY112.2%
TTM net income YoY55.8%
TTM EPS YoY71.4%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—
Margins
Gross margin1,481.2%
Operating margin-2,079.9%
Net margin-1,520.4%
FCF margin—
EBITDA margin-2,026.1%
Returns
ROE—
ROA-87.8%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets291.9%
Debt / equity—
Current ratio0.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $343,000 | $4,000 |
| Cost of revenue | $3.30M | $3.70M |
| Gross profit | $5.92M | $5.48M |
| R&D expense | $2.88M | $3.27M |
| SG&A expense | $7.96M | $10.35M |
| Operating income | -$7.91M | -$16.28M |
| Pretax income | -$12.78M | -$13.09M |
| Net income | -$12.78M | -$13.09M |
| EBITDA | -$7.80M | -$16.19M |
| EPS (basic) | -0.37 | -0.93 |
| EPS (diluted) | -0.37 | -0.93 |
| Weighted avg. shares (diluted) | 34.10M | 14.13M |
| Banking | ||
| Net interest income | -$41,000 | -$33,000 |
| Balance sheet | ||
| Cash & equivalents | $1.75M | $1.77M |
| Receivables | $1.21M | $990,000 |
| Inventory | $256,000 | $326,000 |
| Current assets | $4.06M | $4.18M |
| PP&E, net | $47,000 | $69,000 |
| Intangibles | $310,000 | — |
| Total assets | $5.46M | $5.49M |
| Current liabilities | $3.46M | $5.47M |
| Short-term debt | $236,000 | $229,000 |
| Long-term debt | $1.04M | $1.28M |
| Total debt | $1.28M | $1.51M |
| Total liabilities | $12.39M | $8.05M |
| Shareholders' equity | -$6.93M | -$2.56M |
| Net debt | -$478,000 | -$262,000 |
| Shares outstanding | 43.48M | 17.41M |
| Cash flow statement | ||
| Operating cash flow | -$7.03M | -$12.11M |
| Capital expenditure | $16,000 | $37,000 |
| Free cash flow | -$7.04M | -$12.15M |
| Investing cash flow | -$401,000 | -$37,000 |
| Financing cash flow | $7.42M | $11.06M |
| Depreciation & amortization | $112,000 | $92,000 |
| Stock-based compensation | $531,000 | $1.49M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.